INTRODUCTION:Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients. METHODS:Thirty patients takingolanzapine (10-20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12. RESULTS: The rosiglitazone and placebo groups gained 3.2+/-4.5 and 2.2+/-2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels. DISCUSSION: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
RCT Entities:
INTRODUCTION:Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophreniapatients. METHODS: Thirty patients taking olanzapine (10-20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12. RESULTS: The rosiglitazone and placebo groups gained 3.2+/-4.5 and 2.2+/-2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels. DISCUSSION: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
Authors: Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Erin Hawkes; Chen H Jin; Catherine C Y Pang; William G Honer; Alasdair M Barr Journal: J Psychiatry Neurosci Date: 2012-11 Impact factor: 6.186
Authors: Caleb C Lord; Steven C Wyler; Rong Wan; Carlos M Castorena; Newaz Ahmed; Dias Mathew; Syann Lee; Chen Liu; Joel K Elmquist Journal: J Clin Invest Date: 2017-08-14 Impact factor: 14.808
Authors: Zsuzsanna Literati-Nagy; Kálmán Tory; Botond Literáti-Nagy; Attila Kolonics; László Vígh; László Vígh; József Mandl; Zoltán Szilvássy Journal: Pathol Oncol Res Date: 2012-06-30 Impact factor: 3.201
Authors: Jess G Fiedorowicz; Del D Miller; Jeffrey R Bishop; Chadi A Calarge; Vicki L Ellingrod; William G Haynes Journal: Curr Psychiatry Rev Date: 2012-02-01